Skip to main content

Table 4 Summary of currently published studies using hypofractionated radiotherapy and temozolomide for elderly patients with glioblastomas

From: Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years

AuthorTreatmentnPatientsOS (mo)PFS (mo)
Minniti et al. 2009 [33]RT 30Gy/6fr + TMZ43Age ≥ 70 and KPS ≥609.36.3
Uto et al. 2015 [31]RT 35Gy/10fr + TMZ11Age ≥ 7013.27
Minniti et al. 2012 [29]RT40Gy/15fr + TMZ71Age ≥ 70 and KPS ≥6012.46
Perry et al. 2017 [8]RT40Gy/15fr281Age ≥ 65 and PS 0–27.63.9
RT40Gy/15fr + TMZ2819.35.3
Lombardi et al. 2015 [28]RT40Gy/15fr + TMZ71Age ≥ 65 and PS 0–213.8N/A
RT60Gy/30fr + TMZ16619.4
Chang-Halpenny et al. 2015 [25]RT 35Gy/10fr + TMZ29Age ≥ 655.4N/A
RT60Gy/30fr + TMZ10013
Terasaki et al. 2011 [15]RT45Gy/15fr + TMZ26median 61(39–79)15.69.6
Lim et al. 2015 [27]RT45Gy/15fr + TMZ33Age ≥ 70Age < 70 and PS ≥ 3 or biopsy or rapid growth10.67.5
Harris et al. 2017 [24]Best supportive care31Age ≥ 751.9N/A
RT alone*386.2N/A
RT* + TMZ3313.2N/A
Matsuda et al. 2018 [13]RT45Gy/15fr + TMZ, Bev after recurrence18Age ≥ 75202.5
Present studyRT45Gy/15fr + TMZ or TMZ/Bev30Age ≥ 7512.99.9
  1. RT Radiation therapy, TMZ Temozolomide, Bev Bevacizumab, PFS Progression free survival, OS Overall survival, KPS Karnofsky performance status, PS Performance status, N/A not available
  2. * Radiation therapy was either hypofractionation (40Gy), or longer-course (60Gy)